Eli Lilly and Company LLY
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Eli Lilly and Company gets an algorithmic score of 73/100. It trades at 1,184.63 $, with a bullish technical trend (RSI 56.1) and 35.6% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (102.3%): generates strong profit on equity.
- High net margin (33.5%): pricing power / competitive advantage.
- Sustained revenue growth (31.7% compound annual).
- Low beta (0.66): defensive profile.
- Meaningful dividend (58.00%).
Weaknesses
- —
Fundamentals
| P/E | 39.85 |
| Forward P/E | 24.92 |
| PEG | 1.14 |
| P/B | 31.17 |
| EV/EBITDA | 26.42 |
| P/S | 13.25 |
| ROE % | 102.29 |
| ROA % | 20.36 |
| Gross margin % | 83.40 |
| Operating margin % | 54.22 |
| Net margin % | 33.53 |
| Revenue growth % (y/y) | 47.70 |
| Earnings growth % (y/y) | 26.20 |
| Revenue CAGR % | 31.69 |
| Earnings CAGR % | 48.96 |
| Debt/Equity % | 162.07 |
| Current ratio | 1.35 |
| FCF yield % | 0.56 |
| Dividend yield % | 58.00 |
| Payout % | 21.69 |
Returns
| 1 month | +0.8 % |
| 3 months | -1.1 % |
| 6 months | +34.0 % |
| YTD | +10.2 % |
| 1 year | +64.5 % |
| 3 years | +119.7 % |
| 5 years | +438.6 % |
Risk
| 1-year volatility | 35.6 % |
| Beta | 0.66 |
| 5-year max drawdown | -34.5 % |
| Sharpe 1A | 1.46 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.